iBio (IBIO) Total Liabilities (2011 - 2026)
iBio (IBIO) posted quarterly Total Liabilities of $8.3 million for Q1 2026, up 7.45% year-over-year from $7.7 million in Q1 2025, and up 5.92% quarter-over-quarter from $7.8 million in Q4 2025.
iBio (IBIO) Total Liabilities (2011 - 2026) Analysis & Trends
iBio (IBIO) has reported Total Liabilities for 16 consecutive years, with $8.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 7.45% year-over-year to $8.3 million; the TTM figure through Mar 2026 stood at $8.3 million (up 7.45% YoY), while the FY2025 annual figure was $8.3 million, up 12.08% from the prior year.
- Total Liabilities advanced to $8.3 million in Q1 2026 per IBIO's latest filing, from $7.8 million in the prior quarter.
- Across five years, Total Liabilities topped out at $36.2 million in Q3 2022 and bottomed at $6.8 million in Q3 2024.
- Historically, Total Liabilities has averaged $19.5 million across 5 years, with a median of $24.5 million in 2023.
- Annual changes were most pronounced in 2024 — Total Liabilities tumbled 72.36% — and 2025, when it gained 20.01%.
- iBio's Total Liabilities stood at $33.0 million in 2022, then declined by 24.72% to $24.8 million in 2023, then slumped by 68.57% to $7.8 million in 2024, then climbed by 0.4% to $7.8 million in 2025, then increased by 5.92% to $8.3 million in 2026.
- Business Quant data shows IBIO's Total Liabilities at $8.3 million in Q1 2026, $7.8 million in Q4 2025, and $8.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | iBio | 175.21 Mn | 175.21 Mn | - | 8.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.30 Mn |
| Dec 31, 2025 | 7.83 Mn |
| Sep 30, 2025 | 8.12 Mn |
| Jun 30, 2025 | 8.31 Mn |
| Mar 31, 2025 | 7.72 Mn |
| Dec 31, 2024 | 7.80 Mn |
| Sep 30, 2024 | 6.76 Mn |
| Jun 30, 2024 | 7.41 Mn |
| Mar 31, 2024 | 25.29 Mn |
| Dec 31, 2023 | 24.83 Mn |
| Sep 30, 2023 | 24.47 Mn |
| Jun 30, 2023 | 25.83 Mn |
| Mar 31, 2023 | 27.00 Mn |
| Dec 31, 2022 | 32.98 Mn |
| Sep 30, 2022 | 36.20 Mn |
| Jun 30, 2022 | 35.92 Mn |
| Mar 31, 2022 | 35.99 Mn |
| Dec 31, 2021 | 35.85 Mn |
| Sep 30, 2021 | 43.21 Mn |
| Jun 30, 2021 | 38.40 Mn |